PAZINIB 200 MG

In the supplied oncology record, Palbociclib is associated with Breast Cancer, particularly in the settings described as HR-positive/HER2-negative advanced/metastatic breast cancer; HR-positive/HER2-positive metastatic breast cancer maintenance in current labeled setting. Its pharmacological class is Selective CDK4/6 inhibitor. Inhibits CDK4/6, preventing RB phosphorylation and G1-S cell-cycle progression. The database centers this CDK4/6 inhibitor on HR-positive/HER2-negative advanced or metastatic breast cancer, while also recording a HER2-positive metastatic maintenance setting. The pharmacology is centered on cell-cycle control, with inhibition of CDK4/6 limiting progression through the G1-to-S transition. The treatment category is recorded as Targeted Therapy; CDK4/6 Inhibitor. Regimen examples include Palbociclib + letrozole; palbociclib + fulvestrant; palbociclib + trastuzumab ± pertuzumab + endocrine therapy. Rather than implying one universal use, these combinations show the range of contexts in which the medicine may be incorporated. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Where the same agent is listed for more than one cancer, its role should not be assumed to be interchangeable between diseases. This summary is intentionally non-prescriptive and does not include individualized dosing. Current labeling and relevant disease guidance should be reviewed when the database is used for clinical decision support.